Margins bounce back as Revvity finds an AI spark
- Revvity signed a definitive agreement to sell its China Immunodiagnostics business.
- Q2 operating margins sharply reversed early fears by hitting 29.3 percent.
- Customers building AI validation tools are driving a massive backlog for Revvity instruments.
- Software revenue declined in Q2 but management expects a return to strong growth later this year.
- Finn sees a balanced picture where new catalysts meet high execution stakes.
A cleaner story meets a new catalyst
Revvity is proving its turnaround plan. The company signed a definitive agreement to sell its China Immunodiagnostics business. This removes a policy-heavy overhang and firms up an exit timeline for late 2027. Stripping this out leaves a company better positioned to grow.
Profitability fears from earlier in the year are fading. First-quarter margin drops panicked the market, but Q2 pro forma adjusted operating margins bounced back to 29.3 percent. While a one-time tariff refund helped that number, underlying cost leverage is moving in the right direction.
A new structural growth driver is taking shape. Artificial intelligence generates biological hypotheses, but those ideas need real-world validation. This creates a lab-in-the-loop workflow that directly benefits Revvity. Demand for the company's high-content screening instruments is now outpacing production capacity.
The bear case rests on timing and execution. The Signals software segment dropped 20 percent organically in Q2. Management promises a return to double-digit growth in the second half of the year. If that software recovery stumbles, or if the instrument backlog fails to turn into recognized revenue, the stock could struggle.
Tools, tests, and repeat use
Revvity makes money by selling instruments, reagents, consumables, software, and services. Instruments are the expensive lab machines. Reagents and consumables are the items customers use again and again in testing workflows.
The company serves two broad customer groups. Life Sciences sells into research and drug development. Diagnostics sells into clinical testing areas such as immunodiagnostics and reproductive health.
The model works best when Revvity becomes a permanent part of a customer lab. That creates repeat sales and high switching costs. It breaks when customers delay lab spending or when the company has to sell a lower-margin product mix.
What Revvity sells
Life Sciences Solutions
This includes reagents, consumables, and instruments. AI validation tools have created a massive backlog here.
Software
Software helps labs manage data and workflows. It saw a sharp Q2 decline but is expected to rebound heavily in the second half.
Immunodiagnostics
This business sells tools and tests used in clinical diagnostics. The business excluding China continues to accelerate.
Reproductive Health
This standout segment of Diagnostics grew 11 percent organically in Q2 led by newborn screening.
China Immunodiagnostics
Revvity signed a definitive agreement to sell this business by late 2027 to reduce exposure to Chinese policy pressure.
Two segments, almost even size
Segment mix reflects Q1 2026 revenue where Life Sciences was 51 percent and Diagnostics was 49 percent. The planned China Immunodiagnostics divestiture will alter this mix once closed.
What could go wrong
Software recovery stumbles
High impact · Medium oddsThe software business declined 20 percent organically in Q2 due to tough comparisons. The company expects strong double-digit growth in the second half of the year. If this back-half weighting fails to materialize, the segment will miss targets.
Margin pressure hides behind tariffs
High impact · Medium oddsThe strong Q2 margin beat was aided by a one-time $16 million tariff refund. This refund may mask some underlying cost pressures. The company must prove it can expand margins on organic volume leverage alone.
China divestiture execution
Medium impact · Low oddsA definitive agreement is signed, but the deal does not close until late 2027. Any regulatory delays or stranded costs could disrupt operations and limit the strategic benefit of the sale.
Goodwill impairment in Life Sciences Solutions
Medium impact · Medium oddsThe Life Sciences Solutions unit has a massive $4.5 billion goodwill balance. In late 2025, its fair value exceeded carrying value by a very slim margin. This remains a tail risk until the segment definitively returns to sustained growth.
In one breath
What does Revvity do?
Revvity sells tools used in health science research and clinical testing. Its products include instruments, reagents, consumables, software, diagnostics tools, and services.
Why is Revvity selling its China Immunodiagnostics business?
The business faces heavy policy pressure in China. Revvity is selling it to focus capital on higher-growth, higher-return areas of health sciences.
Is Revvity growing again?
Yes, unevenly. Diagnostics is growing at double digits, and Life Sciences is seeing massive instrument backlogs driven by AI validation needs, though software faces temporary declines.
What is the biggest risk for Revvity stock?
Execution risk in the second half of the year. The company is relying on software returning to double-digit growth and translating its large instrument backlog into real revenue.
